Multicentre evidence for an independent association between third-trimester hypoaldosteronism and preeclampsia

Mei Yang1, Menghui Wang1, Qing Zhu1

  • 1NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NO.91 TianChi Road, Urumqi, 830001, Xinjiang, People's Republic of China.

Scientific Reports
|April 13, 2026
PubMed

The study aimed to investigate the association of plasma aldosterone concentration (PAC) on admission before delivery with preeclampsia, admission blood pressure, and pregnancy outcomes. In this multicenter observational study (May 2023-December 2024), 886 pregnancies (125 preeclampsia, 761 controls) from six hospitals were analyzed. Associations were evaluated using multivariable logistic regression, Spearman's correlation, and restricted cubic spline models, with sensitivity analysis employing Winsorization. Piecewise regression was employed to identify breakpoint and examine threshold effect. Preeclamptic women had significantly lower PAC than controls (16.73 [11.03, 32.59] vs. 28.16 [15.99, 52.82] ng/dL, P < 0.001). Lower PAC was independently associated with preeclampsia (adjusted OR: 0.98; 95% CI 0.98-0.99; P < 0.001) and correlated with higher systolic blood pressure (ρ = -0.170, P < 0.001) and adverse outcomes (P < 0.05). A significant nonlinear relationship was observed (P < 0.001), with a breakpoint at 11.74 ng/dL where each 1-unit increase reduced preeclampsia odds by 30% below it (adjusted OR 0.70; 0.57-0.87) and only by 2% at or above it (adjusted OR 0.98; 0.97-0.99). Lower PAC showed an independent, nonlinear association with preeclampsia, characterized by a threshold effect around 11.74 ng/dL, and is linked to elevated systolic blood pressure and adverse maternal-fetal outcomes.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
773
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
37.3K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
539
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K